Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure.

ABSTRACT:

Background

We aimed to study whether improvement in renal function by serelaxin in patients who were hospitalized for acute heart failure (HF) might explain any potential effect on clinical outcomes.

Methods

We included 6318 patients from the RELAXin in AHF-2 (RELAX-AHF2) study. Improvement in renal function was defined as a decrease in serum creatinine of ≥ 0.3 mg/dL and ≥ 25%, or increase in estimated glomerular filtration rate of ≥ 25% between baseline and day 2. Worsening renal function (WRF) was defined as the reverse. We performed causal mediation analyses regarding 180-day all-cause mortality (ACM), cardiovascular death (CVD), and hospitalization for HF/renal failure.

Results

Improvement in renal function was more frequently observed with serelaxin when compare

SUBMITTER: Beldhuis IE 

PROVIDER: S-EPMC10293419 | biostudies-literature | 2023 Jul

REPOSITORIES: biostudies-literature